Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Denise Luppe"'
Autor:
Kristen Mitchell, Kalyan Mantripragada, Benjamin Kuritzky, Thomas J. Miner, Thomas A. DiPetrillo, Kenneth D. Bishop, Kevin P. Charpentier, Kayla Rosati, Howard Safran, Emmanuel Apor, Denise Luppe, Kimberly Perez
Publikováno v:
American Journal of Clinical Oncology. 39:619-622
Background The Brown University Oncology Research Group performed a phase I study to remove irinotecan from FOLFIRINOX (5-fluorouracil, oxaliplatin, irinotecan, and leucovorin) and substitute nab-paclitaxel. Methods Patients with newly diagnosed adva
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6f2faa0ac908f254a440ca1ad0cbdf8d
https://doi.org/10.1097/coc.0000000000000246
https://doi.org/10.1097/coc.0000000000000246
Autor:
Howard Safran, Kalyan Mantripragada, Kristen Mitchell, Lindsey Cavanagh, Eric I Marks, Rachael Rossiter, Kayla Rosati, Kevin P. Charpentier, Denise Luppe, Thomas J. Miner, Thomas A. DiPetrillo, Andrew Schumacher, Rimini Breakstone, Molly Rago
Publikováno v:
Journal of Clinical Oncology. 36:TPS550-TPS550
TPS550 Background: The FOLFOX-A regimen was developed by BrUOG, in response to the activity of nab-paclitaxel (nP) in metastatic pancreatic cancer (mPC), by substituting nP for irinotecan in FOLFIRINOX. In a phase I/II study of FOLFOX-A in mPC, media
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::16468f15f819a3486e693e43d17dae16
https://doi.org/10.1200/jco.2018.36.4_suppl.tps550
https://doi.org/10.1200/jco.2018.36.4_suppl.tps550
Autor:
Kayla Rosati, David Berz, Kevin P. Charpentier, Kimberly Perez, Thomas Miner, Joel Victor, Santiago Aparo, Gregory Dubel, Denise Luppe, Diane Martel, Pamela Bakalarski, Yoko Eng, Katherine Faricy-Anderson, Howard Safran, Patti Wingate, Angela Plette, Kalyan Mantripragada, Andreas Kaubisch, Joseph Espat
Publikováno v:
American journal of clinical oncology. 38(1)
Purpose To assess the activity and toxicity of lenalidomide for patients with advanced hepatocellular cancer (HCC) previously treated with sorafenib. Materials and methods Patients with advanced HCC who progressed on or were intolerant to sorafenib w
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::83e398be6d4340395e18651eb66499ad
https://pubmed.ncbi.nlm.nih.gov/23648434
https://pubmed.ncbi.nlm.nih.gov/23648434
Autor:
Ritesh Rathore, Nancy Follett, Priscilla Merriam, Denise Luppe, Ariel E. Birnbaum, Terence T. Sio, Thomas A. DiPetrillo, Yacoub Puthawala, Howard Safran, Humera Khurshid, Anthony George Thomas, Donald Joyce, Harry Wanebo
Publikováno v:
American journal of clinical oncology. 37(2)
Objectives To assess the effect on progression-free and overall survival from the addition of cetuximab to paclitaxel-based chemoradiation for patients with squamous cell head and neck cancer from Brown University Oncology Group studies. Methods BrUO
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1a862edef0c4b070ed26a8b022d3b7e4
https://pubmed.ncbi.nlm.nih.gov/23275269
https://pubmed.ncbi.nlm.nih.gov/23275269
A Phase I Study of Dasatinib with Concurrent Chemoradiation for Stage III Non-Small Cell Lung Cancer
Autor:
Kara L. Leonard, Denise Luppe, Thomas Ng, Thomas A. DiPetrillo, Howard Safran, Andrew Schumacher, Kimberly Perez, Humera Khurshid, Kalyan Mantripragada, Maria Constantinou, Kathy Radie-Keane, David Berz, Ariel E. Birnbaum
Publikováno v:
Frontiers in Oncology
Frontiers in Oncology, Vol 2 (2012)
Frontiers in Oncology, Vol 2 (2012)
Objectives: Src family kinases (SFKs) are expressed in non-small cell lung cancer (NSCLC) and may be involved in tumor growth and metastases. Inhibition of SFK may also enhance radiation. The purpose of this study was to evaluate if a maximum dose of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9b2d013dbf8c9ae931700110a249f0aa
https://doi.org/10.3389/fonc.2012.00056
https://doi.org/10.3389/fonc.2012.00056
Autor:
Andrew Schumacher, Howard Safran, Carolyn Bartley, Brittany Cammisa, Alise Lombardo, Cynthia Leach, Denise Luppe, Rachael Rossiter, Kayla Rosati
Publikováno v:
Journal of Clinical Oncology. 33:e17702-e17702
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d420b88488a9284cb682ff20a03146ef
https://doi.org/10.1200/jco.2015.33.15_suppl.e17702
https://doi.org/10.1200/jco.2015.33.15_suppl.e17702
Autor:
Kimberly Perez, Maureen Jean, Kayla Rosati, Denise Luppe, Howard Safran, Adam J. Olszewski, Angela Marie Taber, Humera Khurshid, Ariel E. Birnbaum
Publikováno v:
Journal of Clinical Oncology. 31:8075-8075
8075 Background: mTOR inhibition may overcome PI3K/AKT pathway mediated resistance to anti-EGFR therapy. We performed a phase I study to determine the dose-limiting toxicity (DLT) of ridaforolimus, an investigational oral mTOR inhibitor, in combinati
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b766ffa29971aa7d8b4be8b23221da31
https://doi.org/10.1200/jco.2013.31.15_suppl.8075
https://doi.org/10.1200/jco.2013.31.15_suppl.8075
Autor:
Kimberly Perez, Howard Safran, Lucia Fontes-Borts, Denise Luppe, Kayla Rosati, Maureen Jean, Adam J. Olszewski, Trevor Clark Austin, Bharti Rathore
Publikováno v:
Journal of Clinical Oncology. 31:e15095-e15095
e15095 Background: Cabazitaxel is a semi-synthetic novel taxane with activity in docetaxel refractory prostate cancer. We sought to determine the response rate of cabazitaxel in patients with advanced gastroesophageal adenocarcinoma that had progress
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1f4bb10788a6e9d398dfc1a66bae5d32
https://doi.org/10.1200/jco.2013.31.15_suppl.e15095
https://doi.org/10.1200/jco.2013.31.15_suppl.e15095
Autor:
Trevor Clark Austin, Maureen Jean, Matthew Vrees, Nishit Shah, Adam Klipfel, Thomas A. DiPetrillo, Kimberly Perez, Kayla Rosati, Denise Luppe, Howard Safran
Publikováno v:
Sexual Health. 10:588
Background Human papillomavirus (HPV) DNA is present in the majority of squamous cell cancers of the anus. ADXS11–001 immunotherapy is a live attenuated Listeria monocytogenes (Lm) bioengineered to secrete an HPV-16-E7 fusion protein targeting HPV-
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8e4e3d97191277187c697b3cc3e488c5
https://doi.org/10.1071/shv10n6ab37
https://doi.org/10.1071/shv10n6ab37
Autor:
Kayla Rosati, Kevin P. Charpentier, Denise Luppe, Jack R. Wands, Debora Isdale, Kalyan Mantripragada, Howard Safran, Joel Victor, Angela Marie Taber, Kimberly Perez, Andreas Kaubisch, Yoko Eng, Patti Wingate, Joseph Espat, Gregory J. Dubel, Diane Martel, David Berz, Thomas J. Miner, Katherine E. Faricy-Anderson, Pamela Bakalarski
Publikováno v:
Journal of Clinical Oncology. 30:4098-4098
4098 Background: Lenalidomide inhibits fibroblast growth factor (FGF), vascular endothelial growth factor (VEGF) and multiple tumor growth pathways. There is no standard of care for patients who progress after sorafenib. Therefore, we performed a pha
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7e8857a73b855597b91a9eea737a96bf
https://doi.org/10.1200/jco.2012.30.15_suppl.4098
https://doi.org/10.1200/jco.2012.30.15_suppl.4098